cerca CERCA
Lunedì 03 Ottobre 2022
Aggiornato: 13:49
Temi caldi

announced today it

comunicato stampa

Energy Harbor Launches 24/7 Emission-Free Energy Solution

AKRON, Ohio, Aug. 9, 2022 /PRNewswire/ -- Energy Harbor Corp. announced today it has launched a 24/7 emission-free energy compliance product to meet the growing demand for customers requiring validation that the energy they consume is 100 percent emission-free every hour of every day. Leveraging FlexiDAO's technology and insights from Google Cloud, Energy Harbor will be providing the 24/7 emission-free energy credits (EFEC) created by its nuclear fleet, capable of generating over 32 million credi...

comunicato stampa

Brighton College Further Expands Course Offering in Singapore, Set to Receive Year 8 Pupils

SINGAPORE, July 26, 2022 /PRNewswire/ -- Brighton College (Singapore) https://www.brightoncollege.edu.sg/, a leader in British private education for Children aged 18 months to 11 years, announced today it had received approval from Singapore's Committee for Private Education (CPE) to extend its curriculum and course offerings to pupils aged up to 13 years from August 2025.

ER-REBOA PLUS™ Catheter Earns UK and CE Mark Approval

BOERNE, Texas, May 24, 2021 /PRNewswire/ -- Prytime Medical Devices, Inc. announced today it has received both UK and CE Mark Approval for its next-generation ER-REBOA PLUS™ Catheter. Designed for improved ease of use, this catheter replaces the market defining ER-REBOA™ catheter and represents an important evolution of REBOA technology. The new catheter is REBOA Refined for controlling non-compressible truncal hemorrhage.

Q BioMed Announces Strontium89 will be available as of September 2020 through Named Patient Program for Bone Metastases Pain Palliation in EU and Rest of World

NEW YORK, Aug. 11, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today it is launching a Named Patient Program for its non-opioid bone metastases pain palliation drug, Strontium89 (Strontium Chloride Sr-89 Injection, USP). The Named Patient Program will be available to physicians and patients in the EU and throughout the world, and will be facilitated by Caligor Coghlan Pharma Services (CCPS).

ora in
Prima pagina
articoli
in Evidenza